SOURCE-LINKED STUDY SUMMARY
Incretin hormones: Their role in health and disease.
Abstract summarizedQuality not appraised
- What was studied
- An abstract-based overview explained how the gut peptides GIP and GLP-1 contribute to the incretin response and relate to type 2 diabetes, obesity and incretin-based medicines.
- Who / model studied
- It discusses healthy people and people with type 2 diabetes; no participant count or timeframe is reported.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Oral glucose produced two to three times the insulin response of intravenous glucose. In type 2 diabetes, GIP effectiveness was reduced, while pharmacological GLP-1 receptor stimulation reduced plasma glucose and improved glycaemic control.
- Limitations & context
- No author-stated limitation was available in the abstract. This broad overview does not report a single study sample, assigned comparator or follow-up period.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1111/dom.13129